However, evidence from long-term trials in type 2 diabetes, notably the post-marketing cardiovascular outcome trials (CVOTs) described below, indicated that eGFR subsequently declined at a slower rate with use of an SGLT2 inhibitor than in placebo-treated patients and that albuminuria was less severe. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.